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Clinical trials of typhoid conjugate vaccine (TCV) are ongoing in 4 countries. Early data confirm safety, tolerability, and immuno-
genicity of typhoid conjugate vaccine, and early efficacy results are promising. These data support World Health Organization re-
commendations and planned country introductions. Forthcoming trial data will continue to inform programmatic use of typhoid 
conjugate vaccine.
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Typhoid fever is a systemic infection caused by Salmonella enterica 
serovar Typhi (S. Typhi). The relative importance of water in the 
transmission of typhoid has been recognized since the 19th cen-
tury, before the causative agent of the disease was known. In the 
20th century, many countries witnessed rapid declines in the in-
cidence of typhoid fever following the introduction and improve-
ment of water quality and sanitation systems [1–3].
While typhoid has been eliminated in much of the world, it 
continues to be a substantial public health threat in much of 
Asia, sub-Saharan Africa, and Oceania. Currently, typhoid fever 
disproportionately impacts children and marginalized popula-
tions. The burden of typhoid is likely underestimated due to 
difficulties in surveillance and diagnostic challenges. Current 
global estimates of typhoid fever are at least 11 million cases 
and > 116 000 deaths per year [4–6]. Complications arise in 
10%–15% of untreated typhoid cases and include intestinal per-
foration, hemorrhage, and septic shock [7]. The case fatality rate 
of typhoid fever is 1%–4% with appropriate antibiotic and sup-
portive treatment, and 10%–20% without such treatment [8].
Travelers to typhoid-endemic countries have long had access 
to vaccines. An older-generation, parenteral whole-cell vaccine 
was used extensively in the military. While the vaccine was ef-
ficacious, it was abandoned due to its reactogenicity profile [9]. 
Parenteral typhoid polysaccharide vaccine or an oral live atten-
uated vaccine has been used by travelers to endemic settings 
and for outbreak control. However, neither vaccine has been 
introduced into routine immunization programs. The broader 
use of these vaccines has been limited by the lack of a licensed 
formulation for children < 2 years of age, the need for multiple 
doses in the case of the live oral vaccine, a relatively modest 
level of protection, and limited duration of immunity.
In general, protein-polysaccharide conjugate vaccines have 
the advantages of improved immunogenicity in the youngest 
age groups and longer duration of immunity compared with 
unconjugated polysaccharide vaccines. A capsular polysaccha-
ride of S. Typhi, the Vi antigen, bound to nontoxic recombinant 
Pseudomonas aeruginosa exotoxin A, was highly efficacious in 
Vietnamese children 2–5  years of age, achieving > 90% effi-
cacy against the primary outcome of blood culture–confirmed 
symptomatic S. Typhi infection at 1  year [10]. Unfortunately, 
that vaccine has not yet made it to market. However, research 
and development of TCVs has continued. Nearly 20 years after 
the start of the trial in Vietnam, Typbar-TCV (Bharat Biotech 
International Ltd) became available on the global market and 
was prequalified by the World Health Organization (WHO) in 
2017. This TCV has a Vi polysaccharide conjugated to a tetanus-
toxoid protein carrier, and was first licensed in India in 2013.
In 2018, WHO released updated recommendations on the 
use of typhoid vaccines. Noting the continued high burden of 
typhoid fever and the alarming increase in antimicrobial re-
sistance (AMR) in low- and middle-income countries, WHO 
recommended a single dose of TCV in typhoid-endemic coun-
tries for children 6 months of age and older, plus catch-up vac-
cination for children up to 15 years of age. The WHO further 
stated that decisions on the age of TCV administration, target 
population, and delivery strategy for routine and catch-up 
vaccination should be based on the local epidemiology of ty-
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considerations of the routine childhood immunization pro-
gram. The WHO recommended prioritization to countries with 
the highest burden of disease or a high burden of antimicrobial-
resistant S. Typhi. The statement emphasized that data will be 
needed on coadministration of TCV and other routine child-
hood vaccines, and that countries should strengthen surveil-
lance and monitor occurrence of AMR [7, 10]. Importantly, 
Gavi, the Vaccine Alliance (Gavi) opened a funding window for 
TCV support, and committed US$85 million to support TCVs 
in Gavi-eligible countries [11].
Although the WHO recommendation and Gavi financing 
decision are essential for new vaccine introduction in Gavi-
eligible countries, they are not sufficient for all countries. 
Countries have many competing priorities for limited health-
care dollars. The WHO recommendations were based on safety 
and immunogenicity data and the demonstration of TCV effi-
cacy in a typhoid challenge study performed among adults in 
the United Kingdom [12, 13]. Further information on typhoid 
vaccine effectiveness in endemic settings, and impact on impor-
tant public health outcomes, could further inform country deci-
sion-making and drive country uptake.
The Typhoid Vaccine Acceleration Consortium (TyVAC) 
was launched in 2017 to accelerate the introduction of TCVs in 
low-resource countries. TyVAC has assembled a broad partner-
ship of in-country and international organizations to generate 
necessary data on safety, immunogenicity, and impact of new 
TCVs, to facilitate decision-making at the regional and country 
level, and to ensure country readiness for vaccine introduction 
[14, 15]. Four TyVAC clinical trials are in progress (Table 1), de-
signed to provide data in a variety of settings. Details of the trial 
design have been previously published [16–19].
While the trials are ongoing, TyVAC is committed to pro-
viding data to countries and policy-makers as early as feasible 
(Table 2). For example, safety data from > 100 000 participants 
in the TyVAC trials were presented in December 2018 to the 
Global Advisory Committee on Vaccine Safety (GACVS). The 
GACVS review also included data from early public-sector use 
of TCV in India and Pakistan (Figure  1). GACVS concluded 
that the “safety profile of the Typbar-TCV vaccine is reassuring, 
and no signals of serious adverse events [AEs] were presented.” 
GACVS recommends that countries introducing TCV into their 
routine immunization schedule or into campaigns make every 
effort to ensure robust monitoring of safety. This will provide 
additional data on coadministration of TCV with other routine 
childhood vaccines or in special populations, to detect any sig-
nals that require further investigation, and to maintain public 
confidence in the immunization program [20]. Investigational 
and programmatic introductions with TCV are shown in 
Figure 1.
At the 11th International Conference on Typhoid and Other 
Invasive Salmonelloses, TyVAC data on safety and immunoge-
nicity from the Bangladesh, Malawi, and Nepal trials, and in-
terim efficacy data from Nepal, were presented. While the safety 
results remain blinded, serious AEs represented the pattern of 
typical childhood diseases seen in these settings. In Malawi, 
a subset of approximately 600 children was actively followed, 
Table 1. Summary of Typhoid Vaccine Acceleration Consortium (TyVAC) Clinical Trials (as of 12 December 2019)
Country Design Control Vaccine Ages Start Date Duration No. Vaccinated
Nepal Individually randomized efficacy trial Capsular group A meningococcal conjugate vaccine 9 mo–16 y Nov 2017 2 ya 20 019
Malawi Individually randomized efficacy trial Capsular group A meningococcal conjugate vaccine 9 mo–12 y Feb 2018 2–2.5 yb 28 142
Bangladesh Cluster-randomized effectiveness trial Live attenuated Japanese encephalitis 9 mo–16 y Apr 2018 2 y 67 395
Burkina Faso Individually randomized immunogenicity trial Inactivated poliovirus vaccine 9–23 mo Nov 2018 9 mo 250
aCase-driven interim efficacy.
bCase-driven design with a minimum of 2 years of follow-up.
Table 2. Data Gaps That Will Be Addressed by Typhoid Vaccine Acceleration Consortium (TyVAC)–Sponsored Trials
Data Elements Status
Safety •Bangladesh, Malawi, Nepal trial data—presented to WHO Global Advisory Committee on Vaccine Safety, 2018  




•Bangladesh, Malawi, Nepal trial data—presented at the 11th International Conference on Typhoid and Other Invasive 
Salmonelloses, 26–28 March 2019, Hanoi, Vietnam  
•Studies ongoing in Burkina Faso, Malawi, and Nepal to explore immunogenicity at 9 vs 15 months; with 1 vs 2 doses of 
vaccine; and in HIV-exposed children 
Efficacy and impact in 
endemic setting
•Nepal—first-year efficacy data against laboratory-confirmed infection presented at the 11th International Conference on Ty-
phoid and Other Invasive Salmonelloses, 26–28 March 2019, Hanoi, Vietnam and in peer-reviewed literature. Trial ongoing. 
•Individually randomized trial ongoing in Malawi  
•Cluster-randomized trial followed by catch-up vaccinations ongoing in Bangladesh
Coadministration with 
other vaccines
•Burkina Faso: TCV with measles-rubella, yellow fever, meningitis A  
•Malawi: TCV with measles-rubella 
Duration of protection •Trials currently funded for 2–2.5 y of follow-up 
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Figure 1. Trials and programmatic introductions of typhoid conjugate vaccine in Asia (A) and Africa (B), as of December 2019. Abbreviation: DR Congo, Democratic Republic 
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and mild fever and irritability were the most common AEs in 
the week following vaccination with either TCV or the control 
vaccine, capsular group A  meningococcal conjugate vaccine 
(MenA). In the Bangladesh cluster-randomized trial, which 
used the live attenuated Japanese encephalitis vaccine as the 
control, > 4800 children had AEs assessed at 1 week following 
vaccination. Mild fever was the most common AE in both vac-
cine groups. Similarly, in Nepal, fever and injection site pain 
were the most common AEs 1 week following vaccination with 
TCV or MenA.
The immunogenicity subset consisted of approximately 1500, 
600, and 1300 participants in Bangladesh, Malawi, and Nepal, 
respectively. Based on Vi antibody response 1 month following 
vaccination, robust immunogenicity was observed at all sites 
and in all age groups. These results are comparable to those that 
served as the basis of licensure in India [13]. Longer-term im-
munogenicity sampling is ongoing.
For the randomized controlled efficacy trial in Nepal, the 
primary endpoint was blood culture–confirmed typhoid fever. 
A total of 10 005 participants received TCV and 10 014 received 
MenA. An interim analysis was conducted after a prespecified 
minimum of 45 cases was reached, after approximately 1 year of 
follow-up. The incidence of typhoid fever was 428 per 100 000 
in the MenA control group, confirming the high burden of di-
sease in children in this setting. Blood culture–confirmed ty-
phoid fever occurred in 7 participants who received TCV and 
38 receiving MenA for a vaccine efficacy of 81.6% (95% confi-
dence interval, 58.8%–91.8%; P < .001). The point estimate for 
efficacy was higher when the standard WHO definition of ty-
phoid fever—requiring 3 days of fever—was used [21, 22]. The 
Nepal trial will continue through 2  years of follow-up for all 
participants, at which time analyses of efficacy in subgroups and 
against important public health outcomes, such as hospitaliza-
tions and typhoid complications, will be conducted.
While S. Typhi continues to be a substantial public health 
threat in low-resource settings, the tremendous progress and 
global momentum toward typhoid control were evident at the 
11th International Conference on Typhoid and Other Invasive 
Salmonelloses. Early data from the TyVAC trials presented at 
the conference confirm the safety, tolerability, and immunoge-
nicity of Typbar-TCV. Likewise, the 1-year efficacy results from 
Nepal are promising. These data further support the WHO re-
commendations and the decision by several countries to intro-
duce TCV (Figure  1). The TyVAC trials are ongoing and will 
generate additional data on safety, immunogenicity, and effi-
cacy (including indirect effects and against multiple clinical 
outcomes) in diverse populations. While the promise of such 
data should not delay country decision-making, countries have 
different interests, readiness, and capacities to support intro-
duction. Forthcoming data will continue to inform additional 
country uptake and programmatic use of TCV.
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